Abstract
GLUCAGON exerts positive inotropic and chronotropic effects in the heart1,2. Like its glycogenolytic effect in liver cells3, the cardiac effects of glucagon are often correlated with adenylyl cyclase stimulation2,4–7. Therefore, cyclic AMP-dependent phosphorylation of L-type Ca2+ channels8–10 might be involved in the inotropic effect of glucagon. There have been no reports, however, of the effects of glucagon on the cardiac Ca2+ current (ICa). Also, the physiological effects of glucagon could involve mechanisms other than stimulation of adenylyl cyclase11,12. Here we show that glucagon enhances ICa in frog and rat ventricular myocytes. The effect of glucagon in rats resulted from a stimulation of adenylyl cyclase. In frogs, however, the effect of glucagon on ICa was smaller and occurred at a concentration tenfold lower than in rats, and adenylyl cyclase was not modified. In addition, cAMP potentiated the effect of glucagon on ICa in frog ventricle, which correlated with the observed inhibition by glucagon of low-Km cAMP phosphodiesterase activity. Therefore, this is an example of a hormone that affects cardiac function in a similar way to a variety of synthetic cardiotonic compounds, such as milrinone and Ro-20-1724 (ref. 13). Inhibition of phosphodiesterase activity by glucagon may be essential in animals in which glucagon increases cardiac contractility but does not effectively stimulate adenylyl cyclase7,14,15.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Farah, A. E. & Tuttle, R. J. Pharmac. exp. Ther. 129, 49–55 (1960).
Farah, A. E. Pharmac. Rev. 35, 181–217 (1983).
Sutherland, E. W. & Rall, T. W. J. biol. Chem. 232, 1077–1091 (1958).
Brown, H. D., Chattopadhyay, S. K. & Matthews, W. S. Naturwissenchaften 55, 181–182 (1968).
Robison, G. A., Butcher, R. W., Oye, I., Morgan, H. E. & Sutherland, E. W. Molec. Pharmac. 1, 168–177 (1965).
Murad, F. & Vaughan, M. Biochem. Pharmac. 18, 1053–1059 (1969).
Chatelain, P. et al. Pflügers Arch. 397, 100–105 (1983).
Hofmann, F., Nastainczyk, W., Röhrkasten, A., Scheider, T. & Sieber, M. Trends Pharmac. Sci. 8, 393–398 (1987).
Hartzell, H. C. Prog. Biophys. Molec. Biol. 52, 165–247 (1988).
Fischmeister, R. & Hartzell, H. C. J. Physiol., Lond. 376, 183–202 (1986).
Wakelam, M. J. O., Murphy, G. J., Hruby, V. J. & Houslay, M. D. Nature 323, 68–71 (1986).
Mallat, A. et al. Nature 325, 620–622 (1987).
Beavo, J. A. Adv. Sec. Mess. Phosphoprot. Res. 22, 1–38 (1988).
Clark, C. M. et al. Endocrinology 99, 23–29 (1975).
Wildenthal, K., Allen, D. O., Karlsson, J., Wakeland, J. R. & Clark, C. M. J. clin. Invest. 57, 551–558 (1976).
Hazeki, O. & Ui, M. J. biol. Chem. 256, 2856–2862 (1981).
Hartzell, H. C. & Fischmeister, R. Nature 323, 273–275 (1986).
Fischmeister, R. & Hartzell, H. C. J. Physiol., Lond. 387, 453–472 (1987).
Fischmeister, R. & Hartzell, H. C. Molec. Pharmac. (in the press).
Simmons, M. A. & Hartzell, H. C. Molec. Pharmac. 33, 664–671 (1988).
Masters, S. B., Harden, T. K. & Brown, J. H. Molec. Pharmac. 26, 149–155 (1984).
Buxton, I. L. O. & Brunton, L. L. J. biol. Chem. 26, 6733–6737 (1985).
Houslay, M. D. Biochem. Soc. Trans. 14, 183–193 (1985).
Whittenberg, B. A., White, R. L., Ginzberg, R. D. & Spray, D. C. Circulation Res. 59, 143–150 (1986).
Pollock, H. G., Hamilton, J. W., Rouse, J. B., Ebner, K. E. & Rawitch, A. B. J. biol. Chem. 263, 9746–9751 (1988).
Pecker, F., Duvaldestin, P., Berthelot, P. & Hanoune, J. Clin. Sci. Molec. Med. 57, 313–325 (1979).
Thompson, W. J., Terasaki, W. L., Epstein, P. M. & Strada, S. J. Adv. Cyclic. Nucleotide Res. 10, 69–77 (1979).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Méry, PF., Brechler, V., Pavoine, C. et al. Glucagon stimulates the cardiac Ca2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase. Nature 345, 158–161 (1990). https://doi.org/10.1038/345158a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/345158a0
This article is cited by
-
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Cardiovascular Diabetology (2018)
-
Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts
Acta Pharmacologica Sinica (2009)
-
Myocardial Phosphodiesterases and Regulation of Cardiac Contractility in Health and Cardiac Disease
Cardiovascular Drugs and Therapy (2007)
-
Rolipram reduces the inotropic tachyphylaxis of glucagon in rat ventricular myocardium
Naunyn-Schmiedeberg's Archives of Pharmacology (2004)
-
Einfluß einer veränderten extrazellulären K+- und Mg2+-Konzentration auf die intrazelluläre Ca2+-Homöostase, die Kontraktionskopplung und die Kraft-Frequenz-Beziehung am menschlichen Myokard
Herz (1997)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.